After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
SYRS belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Syros Pharmaceuticals Inc is $6.39M. A total of 1.73 million shares were traded on the day, compared to an average of 9.54M shares.
In the most recent transaction, AKKARAJU SRINIVAS bought 9,333 shares of SYRS for 0.25 per share on Dec 30 ’24. In a previous transaction on Dec 27 ’24, Flagship Pioneering Fund VII, bought 1,331,624 shares at 0.21 per share.
Among the insiders who bought shares, Flagship VentureLabs IV LLC acquired of 21,333 shares on Dec 13 ’24 at a per-share price of $0.23. In another insider transaction, Flagship Pioneering Fund VII, bought 1,000,000 shares at $0.23 per share on Dec 13 ’24.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, SYRS has a high of $7.96 and a low of $0.18.
As of this writing, SYRS has an earnings estimate of -$0.71 per share for the current quarter. EPS was calculated based on a consensus of 4.0 estimates, with a high estimate of -$0.61 per share and a lower estimate of -$0.81.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. SYRS’s latest balance sheet shows that the firm has $130.37M in Cash & Short Term Investments as of fiscal 2021. There were $65.19M in debt and $31.51M in liabilities at the time. Its Book Value Per Share was -$0.41, while its Total Shareholder’s Equity was $85.22M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for SYRS is Buy with a score of 3.00.
